Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-1 in Panic Disorder
NCT06483789Phase 2Terminated
- Sponsor
- HB Biotech
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HB-01 in panic disorder (4 arms), sponsored by HB Biotech. Primary endpoints: Number of Unexpected Panic Attacks at Week 12 and Incidence of Treatment-Emergent Adverse Events at Week 13. Started Oct 2024; status: terminated.
02
Drugs
HB-01
03
Conditions
panic disorder
Beyond the preview
Go deeper on NCT06483789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483789.